drugset
drugset / Trial / NCT05160168

A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

NCT05160168 ↗

Phase 1/2 Terminated 32 enrolled Theseus Pharmaceuticals
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).

Timeline

Start
2022-01-03
Primary completion
2024-02-02
Completion
2024-02-02

Outcome

Outcome not reported

Stopped: “The Sponsor terminated the study due to early dose-limiting toxicities.”

Drugs

EvaluationDrugModalityDoseRoute
Subject THE-630 Unknown — Oral

Indications

connective and soft tissue neoplasm connective tissue neoplasm gastrointestinal stromal tumor